Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

Antibody–drug conjugates (ADCs) typically require internalisation into cancer cells to
release their cytotoxic payload. However, this places stringent constraints on therapeutic …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive
breast cancer has led to dramatic improvements in survival in both early and advanced …

Simple Summary Antibody–drug conjugates (ADC) have shown remarkable therapeutic
activity in a wide range of hematologic and solid tumors. Herein, we discuss the …

To accelerate the translation of cancer nanomedicine, we used an integrated genomic
approach to improve our understanding of the cellular processes that govern nanoparticle …

The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved
for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and …

Antibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class,
combining the precise targeting ability of monoclonal antibodies with the potent cytotoxic …

HER2-positive breast cancer (HER2+ BC) represents 15–20% of all BCs. In the last two
decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors …

Simple Summary Trastuzumab is a humanized antibody that has significantly improved the
management and treatment outcomes of patients with cancers that overexpress HER2 …